Pomerantz Investigates Certara Securities Fraud
Analysis based on 36 articles · First reported May 21, 2026 · Last updated Jul 14, 2026
The market reacted negatively to Certara's poor financial results and the resignation of its CFO, John Gallagher, leading to a significant drop in Certara's stock price. The ongoing investigation by Pomerantz LLP adds further uncertainty and potential financial liabilities for Certara, impacting investor confidence in the company and potentially the broader pharmaceutical software industry.
Pomerantz LLP is investigating Certara, a publicly traded company, for potential securities fraud and other unlawful business practices. This investigation follows Certara's announcement of disappointing first-quarter 2026 financial results, which included a 4% year-over-year decline in services revenue and a 14% decline in services bookings. The company also reported 'softer performance from Tier 1 customers in MIDD services' and a 'mixed' services performance, along with an exit from its regulatory business segment. These disclosures led to a 19% drop in Certara's stock price on May 11, 2026. Further negative sentiment was fueled by the resignation of Certara's Chief Financial Officer, John Gallagher, on June 17, 2026, which caused an additional 8.13% decline in the stock price. Pomerantz LLP is seeking to represent investors who may have suffered losses due to these events.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard